Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from treatment with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. The study, led by scientists at Hospital for Special Surgery in collaboration with rheumatologists at University of Southern California, appears in the recent issue of the journal Arthritis and Rheumatism........